Where do you lose weight first on Mounjaro?

The misconception: Mounjaro 'targets' belly fat or any other specific area

This is the question our prescribers hear most weeks, usually framed as: 'I want to lose my stomach, will Mounjaro go there first?' It's a fair thing to wonder, but the premise needs unpacking. Tirzepatide does not direct the body to burn fat from one place. No licensed medicine works that way. What Mounjaro does is suppress appetite meaningfully and slow gastric emptying, so overall calorie intake falls and the body draws on fat stores for energy. Which stores it draws on first is determined by your individual physiology (your genetics, your sex, your starting weight distribution) not by the drug itself.

That said, clinical observation and the data from the SURMOUNT programme, involving thousands of adults across multiple trials, do show a common pattern. Visceral fat (the fat around the abdominal organs) tends to be metabolically active and is often preferentially mobilised when the body enters a sustained calorie deficit. This is why many people on tirzepatide report their waistband loosening before they notice much change in their hips or thighs. But 'common' is not 'universal', and your experience may differ. Understanding how Mounjaro produces weight loss can help set realistic expectations from the start.

Where changes typically show up first, and why

Across the SURMOUNT-1 trial (published in the New England Journal of Medicine), participants lost an average of around 20–21% of body weight at the highest dose over 72 weeks. The trial measured total body weight rather than regional fat, but consistent with what is known about sustained energy deficit, the most frequently reported early changes among tirzepatide users are: a slimmer abdomen and waist, reduced facial fullness, a less prominent chest, and looser clothing around the upper torso. Lower-body fat (particularly around the hips, thighs and buttocks) tends to shift later in the process, partly because subcutaneous fat in those areas is less metabolically active.

Timing matters here too. The first few weeks of treatment are a settling-in period, the 2.5mg starting dose is designed primarily to help the body adjust, not to produce rapid fat loss. Most people begin to see meaningful changes after the dose has increased at least once, typically from around weeks 8 to 12 onwards. Patience in those early weeks is not the same as the medicine not working.

It's also worth noting that water retention can shift early on, which sometimes gives the impression of rapid fat loss from the face or abdomen before true adipose tissue has moved significantly. Both things can happen simultaneously, but they are different processes.

Factors that shape your personal pattern

Where you lose weight first on Mounjaro will be influenced by several things outside anyone's control. Sex plays a role: people assigned female at birth tend to carry more subcutaneous fat on the hips and thighs (and lose it more slowly from those areas), while those assigned male at birth more commonly carry visceral abdominal fat that shifts earlier. Starting weight matters: the more excess weight someone carries, the more noticeable early changes tend to be. Genetics determine fat distribution patterns, and those patterns hold even when losing weight, the body tends to reverse them in roughly the same order it laid them down.

Diet and activity can influence the speed of overall loss, even if they cannot redirect it regionally. Adequate protein intake and some resistance training during treatment are consistently recommended by clinicians to help preserve muscle mass as fat is lost, something worth discussing with your prescriber. The NHS tirzepatide medicines page covers the broader treatment context, including how lifestyle changes work alongside the medicine.

If you are weighing up the costs involved in private treatment, it is worth understanding that the full picture (clinician review, dose titration support, aftercare) shapes how well you can track and respond to these changes over time.

Side effects that can affect how you feel about your body during treatment

Some people going through a phase of noticeable weight loss also notice 'Mounjaro face', a colloquial term for the more defined, sometimes slightly hollow appearance of the face as fat reduces there. This is not a side effect of the medicine itself; it is fat loss. It is, however, something that can feel unexpected if you didn't anticipate losing weight from your face early on.

Genuine side effects during treatment are mostly gastrointestinal: nausea, loose stools, constipation, and bloating are most common, typically appearing after starting or after a dose increase, and usually settling within one to two weeks. Keeping well hydrated and eating smaller portions helps. If you develop severe, persistent abdominal pain that spreads to your back, seek medical attention promptly, the MHRA has highlighted acute pancreatitis as a known infrequent but serious risk with GLP-1 medicines, and it warrants urgent assessment. You can report any suspected side effect via the MHRA's Yellow Card scheme.

Correct injection technique also matters for consistent absorption. Rotating sites between the abdomen, thigh and upper arm is recommended; our guidance on where to inject Mounjaro for weight loss covers this in full. And because pens need to be stored correctly to stay effective, check our page on whether to keep Mounjaro in the fridge after first use if you are unsure about storage.

If you have questions about how Mounjaro might work for you personally, our prescribers can talk through your situation, and if you are based in Scotland you can find out more about accessing Mounjaro injections in Glasgow through our clinic. Speak to our prescribers through a free consultation, reviewed the same day by a named, GPhC-registered clinician.